glp-1 agonist definition Agonists - What is it? Understanding GLP-1 Agonists
Description
Example registry listing (obesity + cardiovascular disease) One publicly listed Phase 3 study is NCT05882045 (TRIUMPH-3) , which evaluates efficacy and safety in participants with obesity and established cardiovascular disease
Accessed August 17, 2023.
SUSTAIN-6 compared semaglutide to placebo in 3297 patients with T2DM and established CV disease or CV risk factors only [17]
More RCTs are needed to assess the cardiovascular benefits of GLP-1 RAs in HF, regardless of T2DM
Molecular mechanisms of GLP-1RAs The intricate interaction between GLP-1RAs and other cellular signaling pathways is the key to their therapeutic effectiveness
